RadMD Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • RadMD's estimated annual revenue is currently $9.2M per year.(i)
  • RadMD's estimated revenue per employee is $201,000

Employee Data

  • RadMD has 46 Employees.(i)
  • RadMD grew their employee count by -2% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43.2M2156%N/AN/A
#2
$81.8M40710%N/AN/A
#3
$11.7M580%N/AN/A
#4
$1011.8M5034-9%N/AN/A
#5
$44.8M2231%N/AN/A
#6
$13.1M655%N/AN/A
#7
$16.5M8241%N/AN/A
#8
$17.3M86-5%N/AN/A
#9
$67.9M33823%N/AN/A
#10
$14.9M747%N/AN/A
Add Company

What Is RadMD?

RadMD is the global leader in providing medical imaging expertise for clinical trials. Founded by Drs. Richard Patt and Kohkan Shamsi, both radiologists, who each bring over 20 years of pharmaceutical clinical development, regulatory, and imaging experience. RadMD’s expertise is focused on developing clinico-regulatory compliant strategies to implement imaging efficacy and safety endpoints in trials from Phase 1 (e.g. improving go/no-go decision making) through Phase 4 (e.g. imaging-enabled registries). We are the only company that offers category 1 ACCME-certified web based training and testing on imaging efficacy criteria (i.e., RECIST, Cheson, PAMRIS, etc.), conducted through the Blinded Reader and Investigator Training Institute (BRITI), for site investigators and sponsor/CRO personnel. Logistics, training, and performance management are included in RadMD’s services when using our more than 600 trained and certified independent image and clinical reviewers. Our experts include radiologists, oncologists, cardiologists, pathologists, gastroenterologists, dermatologists, and other specialized physicians.

keywords:N/A

N/A

Total Funding

46

Number of Employees

$9.2M

Revenue (est)

-2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.2M46-12%N/A
#2
$5.5M4724%N/A
#3
$35M484%N/A
#4
$11.4M497%N/A
#5
$9.1M504%N/A